Analysed CALCIMEDICA INC (CALC:NASDAQ) News Sources
CalciMedica’s stock drops 75% on acute kidney injury trial termination
29-01-2026
clinicaltrialsarena.com
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
28-01-2026
yahoo.com
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
12-11-2025
yahoo.com
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
12-11-2025
yahoo.com
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
10-11-2025
yahoo.com
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
14-10-2025
yahoo.com
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
02-09-2025
yahoo.com
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
12-08-2025
yahoo.com
What is the current price of CALCIMEDICA INC (CALC:NASDAQ)?
The current price of CALCIMEDICA INC (CALC:NASDAQ) is $0.6046.
CALCIMEDICA INC (CALC:NASDAQ) absolute price change since previous trading day?
The absolute price change of CALCIMEDICA INC (CALC:NASDAQ) since the previous trading day is $-0.0573.
CALCIMEDICA INC (CALC:NASDAQ) percentage price change since previous trading day?
The percentage price change of CALCIMEDICA INC (CALC:NASDAQ) since the previous trading day is -8.6569%.
What is the most recent average sentiment score for CALCIMEDICA INC (CALC:NASDAQ)?
The most recent average sentiment score for CALCIMEDICA INC (CALC:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for CALCIMEDICA INC (CALC:NASDAQ)?
The most recent sentiment for CALCIMEDICA INC (CALC:NASDAQ) is .
SEC-8K** Filing Available For CALCIMEDICA INC (CALC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.